Semaglutide plus anti-amyloid antibodies for Alzheimer's
Combination Therapy with Semaglutide and Anti-Amyloid Antibodies for Alzheimers Disease
['FUNDING_R01'] · BRIGHAM AND WOMEN'S HOSPITAL · NIH-11266230
Combining semaglutide (a diabetes drug) with anti-amyloid antibody treatments to help people with early Alzheimer's improve thinking and lower the risk of brain swelling or tiny bleeds.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRIGHAM AND WOMEN'S HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11266230 on ClinicalTrials.gov |
What this research studies
Researchers plan to give semaglutide, a GLP-1 receptor drug with anti-inflammatory and blood-vessel benefits, alongside anti-amyloid antibodies like aducanumab or lecanemab to see if the combo is safer and more effective. They will use laboratory and animal models that mimic Alzheimer's disease and examine effects on brain blood vessels, inflammation, and amyloid clearance, with attention to APOE-e4 related risks. The team will measure markers of amyloid-related imaging abnormalities (ARIA), microhemorrhages, and cognitive-related outcomes to understand safety and potential cognitive benefit. Results are intended to inform whether this combination could be moved into human trials or guide care for people receiving anti-amyloid therapies.
Who could benefit from this research
Good fit: People with early-stage Alzheimer's disease (mild cognitive impairment or mild dementia due to Alzheimer's) who are eligible for or considering anti-amyloid antibody therapy would be the most relevant candidates.
Not a fit: People with advanced Alzheimer's, non-Alzheimer's causes of dementia, or those who cannot take GLP-1R agonists are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, the approach could improve cognitive outcomes and reduce ARIA-related swelling or microbleeds in people receiving anti-amyloid antibody treatment.
How similar studies have performed: GLP-1 drugs have shown benefits in animal models and semaglutide is being tested in large Phase 3 trials for early Alzheimer's, but combining semaglutide with anti-amyloid antibodies to reduce ARIA is a novel idea not yet proven in patients.
Where this research is happening
BOSTON, UNITED STATES
- BRIGHAM AND WOMEN'S HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEMERE, CYNTHIA A — BRIGHAM AND WOMEN'S HOSPITAL
- Study coordinator: LEMERE, CYNTHIA A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Adult-Onset Diabetes Mellitus